Prof. Yong Zhang 张勇
Chief Physician, Professor
Department of Urology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Robotic and laparoscopic minimally invasive surgery for urologic tumors, including bladder, kidney, prostate, ureteral, testicular, and adrenal cancers. Expertise includes radical cystectomy with neobladder reconstruction, nerve-sparing prostatectomy, partial nephrectomy, and complex tumor resections.
Dr. Zhang is Deputy Director of Urology at the Cancer Hospital, Chinese Academy of Medical Sciences, and Director at its Hebei branch. With 29 years of experience, Dr. Zhang trained in robotic surgery at Lund University (2007) and Cleveland Clinic (2019). A certified da Vinci surgeon, Dr. Zhang has performed over 4,500 minimally invasive procedures.
Professional roles
- Member, Chinese Medical Association
- Deputy Secretary-General, Minimally Invasive and Robotics Group, Urology Branch, Chinese Medical Doctor Association
- Member, Robotics Group, Urology Branch, Chinese Medical Association
- Vice Chair, Urologic Oncology Committee, Beijing Cancer Prevention and Control Society
Name order: in Chinese the family name comes first (Zhang Yong). Papers usually list the name as Yong Zhang or Zhang Y.
Selected publications
47 papers on PubMed matched by name and affiliation; 14 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Thorac Dis, 2026 (senior author): Biosafety of micron-sized Fe(3)O(4) magnetic fluid for pulmonary injection: a preclinical study toward lung nodule localization. PubMed 42182788
- Pharmaceuticals (Basel), 2026 (senior author): Identification and Functional Analysis of Targets of Dehydrodiisoeugenol in Bladder Cancer Based on Chemoproteomics-Based Profiling. PubMed 42075905
- Sci Rep, 2025 (first author): Impact of Tregs on tumor regression in locally advanced G/GEJ cancer patients undergoing neoadjuvant chemoimmunotherapy. PubMed 40775000
- FASEB J, 2025 (senior author): AP1M2 Drives Gemcitabine-Cisplatin Chemoresistance by Enhancing RAD54B-Associated DNA Repair in Bladder Cancer. PubMed 40387455
- BMC Public Health, 2025 (senior author): Delays in follow-up among women with abnormal results: a retrospective study based on population-based breast cancer screening programme in China. PubMed 40361018
- BMC Womens Health, 2024 (senior author): Awareness, attendance, and attitudes toward cervical cancer screening among HIV-positive Chinese women in Yunnan province: a cross-sectional study. PubMed 39633302
- J Cancer Res Clin Oncol, 2024 (senior author): Establishment of a prognostic risk model for prostate cancer based on Gleason grading and cuprotosis related genes. PubMed 39085482
- Eur J Med Res, 2024 (senior author): Exploration of tissue fixation methods suitable for digital pathological studies of the testis. PubMed 38858777
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion